Solid Tumor
Conditions
Keywords
14C-TH-302, Advanced or Metastatic Solid Tumors, Evofosfamide
Brief summary
This is an open-label, Phase 1, two-center trial to evaluate the mass balance and metabolite profile of carbon 14 \[14C\]-labeled TH-302 (Label 1 and Label 2) followed by subsequent treatment with unlabeled TH-302 in cancer subjects with locally advanced or metastatic solid tumors.
Interventions
DRUG[14C] TH-302 (Label 1)
\[14C\]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
DRUG[14C] TH-302 (Label 2)
\[14C\]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
DRUGUnlabeled TH-302
Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m\^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m\^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
Sponsors
Threshold Pharmaceuticals
Merck KGaA, Darmstadt, Germany
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male subject with pathologically or cytologically confirmed solid tumor which is locally advanced or metastatic, and either refractory to the standard therapy or for which no effective standard therapy is available * Subject has measurable and evaluable disease as RECIST version 1.1 * Age greater than or equal to (\>=) 18 years and less than or equal to (=\<) 70 years * Body mass index (BMI) \>= 19 and =\< 33 kilogram per square meter (kg/m\^2), body weight greater than (\>) 50 kilogram (kg) * Eastern cooperative oncology group (ECOG) performance status of 0 to 1 * Life expectancy of at least 3 months * At least 4 weeks from previous cytotoxic chemotherapy or radiation therapy and at least 5 half-lives or 6 weeks, whichever is longer, after targeted or biologic therapy * Acceptable renal function, liver function and hematologic status as defined in the protocol * Other protocol-defined inclusion criteria could apply
Exclusion criteria
* New York Heart Association (NYHA) Class 3 or 4 congestive heart disease, myocardial infarction within 6 months, unstable arrhythmia, symptomatic ischemic heart disease or symptomatic peripheral arterial vascular disease * Severe chronic obstructive or other pulmonary disease with hypoxemia as defined in the protocol * Major surgery, other than diagnostic surgery, =\< 28 days prior to Day 1. Subject must have completely recovered from surgery * Primary brain tumors or clinical evidence of active brain metastasis as defined in the protocol * Treatment with strong inhibitors and/or inducers of drug metabolic enzymes or drug transporter as defined in the protocol * Participation in a drug trial within 30 days prior to start of trial medication. Participation in a trial involving administration of 14C-labeled compound(s) within last 6 months prior to start of study drug * Inability to understand the protocol requirements, instructions and trial-related restrictions, the nature, scope, and possible consequences of the trial * Legal incapacity or limited legal capacity * Other protocol-defined
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics profile in plasma: Cmax, Tmax, AUC (0-t), lambda_z, t1/2, AUC (0-infinity), CL, Vss, Vz, MRT for TH-302 and its active metabolite Br-IPM | Days 1 and 8 of Cycle 1 |
| Pharmacokinetics profile in excreta: Cumulative Ae (0-t), Ae (0-infinity), percent radioactive dose excreted in urine and feces, AeUF, CLR, CLNR for TH-302 and its active metabolite Br-IPM | Day 1 of Cycle 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total and free plasma concentrations of TH-302 in plasma | Day 1 of Cycle 1 | — |
| Number of subjects with Treatment-emergent adverse events (TEAEs) | Baseline up to Day 30 after the last dose of study treatment | — |
| Unbound fraction (fu) of TH-302 in plasma | Day 1 of Cycle 1 | — |
| Number of subjects with tumor response according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) | Up to 1 year | Tumor response was defined as the occurrence of complete response (CR) or partial response (PR) based on the investigator's assessment according to RECIST v 1.1. |
| Blood to plasma ratio of total 14C-radioactivity | Days 1 and 8 of Cycle 1 | — |
Countries
Germany
Outcome results
None listed